Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Post by jopatcloon Mar 28, 2024 2:33pm
77 Views
Post# 35958656

high rate of success.to focus on closing sales .Multiple!$$

high rate of success.to focus on closing sales .Multiple!$$Added Mr. MacNaught “Over the next month we will continue
to focus on closing sales for VMS+3.2,
preparing for the AEPC conference in May, submitting VMS+4.0 to FDA for 510(k) clearance and optimizing our internal processes to support growth. During this time, I will be devoting more time and attention to the U.S. market to ensure that Ventripoint achieves a high rate of success.

Exciting Developments in Cardiac Health: Why Ventripoint is a Game-Changer

<< Previous
Bullboard Posts
Next >>